Advanced

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases

Hoes, J. N.; Jacobs, J. W. G.; Boers, M.; Boumpas, D.; Buttgereit, F.; Caeyers, N.; Choy, E. H.; Cutolo, M.; Da Silva, J. A. P. and Esselens, G., et al. (2007) In Annals of the Rheumatic Diseases 66(12). p.1560-1567
Abstract
Objective: To develop evidence-based recommendations for the management of systemic glucocorticoid ( GC) therapy in rheumatic diseases. Methods: The multidisciplinary guideline development group from 11 European countries, Canada and the USA consisted of 15 rheumatologists, 1 internist, 1 rheumatologist-epidemiologist, 1 health professional, 1 patient and 1 research fellow. The Delphi method was used to agree on 10 key propositions related to the safe use of GCs. A systematic literature search of PUBMED, EMBASE, CINAHL, and Cochrane Library was then used to identify the best available research evidence to support each of the 10 propositions. The strength of recommendation was given according to research evidence, clinical expertise and... (More)
Objective: To develop evidence-based recommendations for the management of systemic glucocorticoid ( GC) therapy in rheumatic diseases. Methods: The multidisciplinary guideline development group from 11 European countries, Canada and the USA consisted of 15 rheumatologists, 1 internist, 1 rheumatologist-epidemiologist, 1 health professional, 1 patient and 1 research fellow. The Delphi method was used to agree on 10 key propositions related to the safe use of GCs. A systematic literature search of PUBMED, EMBASE, CINAHL, and Cochrane Library was then used to identify the best available research evidence to support each of the 10 propositions. The strength of recommendation was given according to research evidence, clinical expertise and perceived patient preference. Results: The 10 propositions were generated through three Delphi rounds and included patient education, risk factors, adverse effects, concomitant therapy ( ie, non-steroidal anti-inflammatory drugs, gastroprotection and cyclo-oxygenase-2 selective inhibitors, calcium and vitamin D, bisphosphonates) and special safety advice ( ie, adrenal insufficiency, pregnancy, growth impairment). Conclusion: Ten key recommendations for the management of systemic GC-therapy were formulated using a combination of systematically retrieved research evidence and expert consensus. There are areas of importance that have little evidence ( ie, dosing and tapering strategies, timing, risk factors and monitoring for adverse effects, perioperative GC-replacement) and need further research; therefore also a research agenda was composed. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of the Rheumatic Diseases
volume
66
issue
12
pages
1560 - 1567
publisher
British Medical Association
external identifiers
  • wos:000250902600003
  • scopus:36749001123
ISSN
1468-2060
DOI
10.1136/ard.2007.072157
language
English
LU publication?
yes
id
1656e374-0561-4e86-b2a5-2f4fd0df47b3 (old id 972326)
date added to LUP
2008-01-29 15:31:16
date last changed
2017-11-12 03:54:07
@article{1656e374-0561-4e86-b2a5-2f4fd0df47b3,
  abstract     = {Objective: To develop evidence-based recommendations for the management of systemic glucocorticoid ( GC) therapy in rheumatic diseases. Methods: The multidisciplinary guideline development group from 11 European countries, Canada and the USA consisted of 15 rheumatologists, 1 internist, 1 rheumatologist-epidemiologist, 1 health professional, 1 patient and 1 research fellow. The Delphi method was used to agree on 10 key propositions related to the safe use of GCs. A systematic literature search of PUBMED, EMBASE, CINAHL, and Cochrane Library was then used to identify the best available research evidence to support each of the 10 propositions. The strength of recommendation was given according to research evidence, clinical expertise and perceived patient preference. Results: The 10 propositions were generated through three Delphi rounds and included patient education, risk factors, adverse effects, concomitant therapy ( ie, non-steroidal anti-inflammatory drugs, gastroprotection and cyclo-oxygenase-2 selective inhibitors, calcium and vitamin D, bisphosphonates) and special safety advice ( ie, adrenal insufficiency, pregnancy, growth impairment). Conclusion: Ten key recommendations for the management of systemic GC-therapy were formulated using a combination of systematically retrieved research evidence and expert consensus. There are areas of importance that have little evidence ( ie, dosing and tapering strategies, timing, risk factors and monitoring for adverse effects, perioperative GC-replacement) and need further research; therefore also a research agenda was composed.},
  author       = {Hoes, J. N. and Jacobs, J. W. G. and Boers, M. and Boumpas, D. and Buttgereit, F. and Caeyers, N. and Choy, E. H. and Cutolo, M. and Da Silva, J. A. P. and Esselens, G. and Guillevin, L. and Hafstrom, I. and Kirwan, J. R. and Rovensky, J. and Russell, A. and Saag, K. G. and Svensson, Björn and Westhovens, R. and Zeidler, H. and Bijlsma, J. W. J.},
  issn         = {1468-2060},
  language     = {eng},
  number       = {12},
  pages        = {1560--1567},
  publisher    = {British Medical Association},
  series       = {Annals of the Rheumatic Diseases},
  title        = {EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases},
  url          = {http://dx.doi.org/10.1136/ard.2007.072157},
  volume       = {66},
  year         = {2007},
}